Hypersensitivity to adrenomedullin in post-traumatic headache: a randomized crossover study.
Adrenomedullin (ADM), a vasoactive member of the calcitonin peptide family with receptor-signalling overlap with calcitonin gene-related peptide (CGRP), has emerged as a candidate therapeutic target in migraine. Given the striking clinical parallels between migraine and persistent post-traumatic headache (PTH), we investigated whether ADM-responsive signalling contributes to migraine-like headache in adults with persistent PTH attributed to mild traumatic brain injury. We conducted a single-centre, randomised, double-blind, placebo-controlled, two-way crossover study in adults with persistent PTH and no pre-trauma history of migraine. On two experimental days separated by at least 7 days, participants received 20-minute intravenous infusions of ADM (19.9 pmol kg⁻¹ min⁻¹) and isotonic saline as the matched inactive comparator (placebo) in randomised sequence. Headache outcomes were recorded for 12 hours. The primary outcome was the within-participant incidence of experimentally induced migraine-like headache. The secondary outcome was the within-participant difference in baseline-corrected area under the curve (AUC) for headache intensity from 0 to 12 hours. Of 158 individuals assessed for eligibility, 21 were randomised, completed both periods and were analysed. Participants had a mean age of 34.3 years, 19 (90%) were female, and 18 (86%) reported a migraine-like phenotype. Migraine-like headache occurred in 17 of 21 participants (81%) after ADM and four of 21 (19%) following placebo. Fourteen participants developed migraine-like only after ADM and one only following placebo, yielding a paired absolute risk difference of 61.9 percentage points (95% CI 29.7-80.6; one-sided P < 0.001; two-sided P = 0.001). Baseline-corrected headache-intensity AUC was higher after ADM than placebo (median 1,110 [IQR 315-2205] versus 420 [-160 to 565]; P = 0.006). Median time to onset of migraine-like headache was 30 minutes after ADM and 390 minutes following placebo. Fifteen participants reported that the ADM-induced headache resembled their usual migraine-like headache episodes, and rescue medication was used by 10 participants after ADM and two after placebo. These findings identify pronounced responsiveness to ADM-linked signalling in persistent PTH and support the ADM pathway as a candidate target for mechanism-based therapeutic development, pending confirmation in independent cohorts and complementary preclinical studies.
Authors
- Ksenija Cucanić (ORCID: https://orcid.org/0000-0002-1442-4897)
- Messoud Ashina (ORCID: https://orcid.org/0000-0003-0951-5804)
- Haidar M. Al‐Khazali (ORCID: https://orcid.org/0000-0001-7015-3369)
- Zahra Hakimzadeh (ORCID: https://orcid.org/0000-0002-3046-9753)
- Berkay Alpay (ORCID: https://orcid.org/0000-0001-8531-5690)
- Annette Maria Fuchs
- Håkan Ashina (ORCID: https://orcid.org/0000-0002-6268-727X)
- Anna G. Melchior (ORCID: https://orcid.org/0009-0003-7961-5103)
Institutions
- University of Copenhagen (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Technical University of Denmark (DK)
Publication Details
- Journal
- PubMed
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1093/brain/awag401
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00